Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMK-S005 for Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users
NCT02342470Phase 2Completed
- Sponsor
- PharmaKing
- Start
- Nov 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of s-allylcysteine in peptic ulcer disease (PUD) (4 arms), sponsored by PharmaKing. Primary endpoint: The incidence of endoscopic peptic ulcer at 12 weeks. Started Nov 2014; status: completed.
02
Drugs
s-allylcysteine
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT02342470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342470.